Table 1.
Pretreatment characteristics
| Covariate | No. of eligible patients (n=629) | % of total |
|---|---|---|
| Age, years | ||
| Median | 63 | |
| Minimum-maximam | 20–91 | |
| Gender | ||
| Males | 554 | 88.1% |
| Females | 75 | 11.9% |
| Race | ||
| White | 562 | 89.3% |
| Others | 67 | 10.7% |
| Primary site | ||
| Esophagus | 95 | 15.1% |
| EGJ | 534 | 84.9% |
| Histology | ||
| Adenocarcinoma | 550 | 87.4% |
| Squamous cell carcinoma | 79 | 12.6% |
| Histologic Grade | ||
| Well-Moderate | 298 | 47.4% |
| Poorly | 331 | 52.6% |
| Baseline T Stage | ||
| T1 | 11 | 1.7% |
| T2 | 64 | 10.2% |
| T3 | 537 | 85.4% |
| T4 | 17 | 2.7% |
| Baseline N Stage | ||
| N0 | 221 | 35.1% |
| N1 | 408 | 64.9% |
| Baseline M Stage | ||
| M0 | 614 | 97.6% |
| M1a | 15 | 2.4% |
| Baseline Stage | ||
| Stage I | 10 | 1.6% |
| Stage II | 236 | 37.5% |
| Stage III | 368 | 58.5% |
| Stage IVA | 15 | 2.4% |
Abbreviation: EGJ, esophagogastric junction